Related Experiment Videos
Respiratory syncytial virus vaccine development
1Department of Pediatrics, Vanderbilt University Medical Center, D-7235 Medical Center North, 1161 21st Avenue South, Nashville, TN 37232-2581, USA. james.crowe@vanderbilt.edu
Insights
Developing a respiratory syncytial virus (RSV) vaccine for infants faces challenges with animal models and infant immunity. Recent progress includes live attenuated and subunit vaccine candidates in clinical trials.
Area of Science:
- Pediatrics
- Vaccinology
- Virology
Background:
- Respiratory Syncytial Virus (RSV) is a major cause of infant respiratory illness.
- Existing challenges include the lack of ideal animal models and infant immunological immaturity.
- Previous vaccine development efforts have faced significant hurdles.
Purpose of the Study:
- To review the obstacles in developing an effective RSV vaccine for infants.
- To highlight recent advancements in RSV vaccine development.
- To provide an overview of current vaccine candidates in clinical trials.
Main Methods:
- Literature review of RSV vaccine development.
- Analysis of challenges in animal modeling and infant immunization.
- Summary of progress in live attenuated and protein subunit vaccine candidates.
Main Results:
- Significant progress has been made in developing novel RSV vaccine candidates.
- Live attenuated viruses and protein subunit approaches show promise.
- Multiple RSV vaccine candidates are progressing through early clinical trials.
Conclusions:
- Despite obstacles, advancements in RSV vaccine technology are notable.
- Ongoing clinical trials are crucial for evaluating vaccine efficacy and safety.
- The development of an infant RSV vaccine remains a critical public health goal.
Abstract:
Development of an RSV vaccine for infants has been hindered by the lack of an ideal animal model that exhibits disease, and the challenge of effectively immunizing very young infants who are immunologically immature. Nevertheless, significant progress has been made recently in developing live attenuated viruses and protein subunit vaccine candidates. Numerous vaccine candidates are currently in early clinical trials. This paper reviews the significant obstacles to development of RSV vaccines, and the progress made to date.